The draft, whose fate as of June 23 this year can already be followed on the pages of the Polish Parliament, differs slightly from the latest version, published by the Government Legislation Center. Unfortunately, these are not differences that would significantly and positively change the assessment of its impact on the pharmaceutical market. What has changed (among other things), compared to the version from March this year. (i.e., the last one published on the RCL website)?
- The amendment to Article 4(11) of the Law, which stipulates that statutory payback must be borne by applicants who have risk-sharing instruments in place, has been dropped - under the current version of DNUR, these entities would have paid to the budget the difference between the value of the payback resulting from the RSS and the statutory payback;
- The provision amending Article 5 of the Reimbursement Law was removed - it was supposed to change the rules for calculating the price per DDD of a compounded drug;
- A lower and upper limit on the official wholesale margin has been introduced. As previously announced, the DNUR provides for an increase in the wholesale margin to 6% ...